// App-Quantinova.ai

1877 : Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial

Researchers

Presenter

  • Arkadi Chines

Principal Investigators

  • Roland Chapurlat

  • Joseph Foldes

  • Xavier Nogues

  • Roberto Civitelli

  • Tobias De Villiers

  • Fabio Massari

  • Cristiano A. Zerbini

  • Wenjing Yang

  • Chris Recknor

  • Cesar Libanati

Medical Centers

  • CHU de Quebec and Laval University, Quebec, QC, Canada

  • Amgen Inc, Thousand Oaks, CA

  • INSERM UMR , Universite de Lyon, Lyon, France

  • Hadassah-Hebrew-University-Medical-Cente, Jerusalem, Israel

  • IMIM (Institut Hospital del Mar d'Investigacions Mediques), Barcelona, Spain

  • Washington University School of Medicine, St. Louis, MO

  • Stellenbosch University, Stellenbosch, South Africa

  • Instituo de Investigaciones Cardiologicas UBA, Buenos Aires, Argentina

  • Centro Paulista de Investigacoe s Clinicas, Sao Paulo, Brazil

  • United Osteoporosis Centers, Gainesville, GA

  • UCB Pharma, Brussels, Belgium

Locations

  • Canada

  • United States

  • France

  • Israel

  • Spain

  • South Africa

  • Argentina

  • Brazil

  • Belgium

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Osteoporosis

Biomarkers

  • Bone Mineral Density

Drug/Treatment

  • Alendronate sodium

  • Romosozumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved